Phase Ib of L-NMMA and Pembrolizumab

Conditions:   Non-Small Cell Lung Cancer;   Malignant Melanoma;   Head and Neck Squamous Cell Carcinoma;   Classical Hodgkin Lymphoma;   Urothelial Carcinoma Bladder;   DNA Repair-Deficiency Disorders
Interventions:   Drug: L-NMMA;   Drug: Pembrolizumab
Sponsor:   Jorge G. Darcourt
Not yet recruiting - verified July 2017

http://ift.tt/2tZsuOi